iShares Biotechnology ETF (IBB)
| Assets | $8.65B |
| Expense Ratio | 0.44% |
| PE Ratio | 24.67 |
| Shares Out | 49.50M |
| Dividend (ttm) | $0.39 |
| Dividend Yield | 0.22% |
| Ex-Dividend Date | Dec 16, 2025 |
| Payout Ratio | 5.49% |
| 1-Year Return | +27.97% |
| Volume | 1,386,134 |
| Open | 173.14 |
| Previous Close | 173.88 |
| Day's Range | 172.16 - 175.67 |
| 52-Week Low | 107.43 |
| 52-Week High | 179.64 |
| Beta | 0.79 |
| Holdings | 262 |
| Inception Date | Feb 5, 2001 |
About IBB
Fund Home PageThe iShares Biotechnology ETF (IBB) is an exchange-traded fund that is based on the NYSE Biotechnology index. The fund tracks the performance of a modified market-cap-weighted index of US biotechnology companies listed on US exchanges. IBB was launched on Feb 5, 2001 and is issued by BlackRock.
Top 10 Holdings
49.38% of assets| Name | Symbol | Weight |
|---|---|---|
| Gilead Sciences, Inc. | GILD | 9.16% |
| Vertex Pharmaceuticals Incorporated | VRTX | 8.88% |
| Amgen Inc. | AMGN | 8.81% |
| Regeneron Pharmaceuticals, Inc. | REGN | 6.68% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 3.68% |
| Insmed Incorporated | INSM | 2.70% |
| argenx SE | ARGX | 2.68% |
| Natera, Inc. | NTRA | 2.43% |
| Biogen Inc. | BIIB | 2.36% |
| BeOne Medicines AG | ONC | 2.00% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 16, 2025 | $0.1831 | Dec 19, 2025 |
| Sep 16, 2025 | $0.08284 | Sep 19, 2025 |
| Mar 18, 2025 | $0.12117 | Mar 21, 2025 |
| Dec 17, 2024 | $0.06237 | Dec 20, 2024 |
| Sep 25, 2024 | $0.20047 | Sep 30, 2024 |
| Mar 21, 2024 | $0.12599 | Mar 27, 2024 |
News
Revenge Of The Dividend Stocks
Dividend stocks have sharply outperformed AI-related tech stocks since November 2025, reversing a multi-year trend. I see the rally in dividend ETFs like SCHD as overextended, prompting a pause in new...
IBB: Beyond The 2025 Surge, Biotech Breakout
iShares Biotechnology ETF is rated a BUY, offering a balanced entry into biotech with large-cap stability and strong recent performance. IBB benefits from catalysts including accelerating M&A and AI-d...
IBB: Biotech's Hot Streak May Cool
iShares Biotechnology ETF (IBB) earns a reiterated hold rating as it consolidates near all-time highs with balanced risk/reward. IBB's valuation is fair at a 19x P/E and low 3% EPS growth, resulting i...
Nvidia–Eli Lilly Tie-Up Shows Why AI Drug Discovery Is The Next ETF Battleground
NVIDIA Corp.'s (NASDAQ: NVDA) and Eli Lilly and Co.'s (NYSE: LLY) newly announced $1 billion AI co-innovation lab underscores how artificial intelligence is spreading beyond data centers into medicine...
Funding for Risky Biotechs Is Returning
Publicly traded drug developers sold more than $13 billion of shares in the fourth quarter, the most in more than four years.
Pharma stocks are set to take off this year, says UBS' Michael Yee
Michael Yee, global head of biotech research at UBS, joins CNBC's ‘Squawk on the Street' to explain why he is bullish on biopharma stocks this year, the pharma M&A outlook, and more.
Mizuho's Jared Holz on what biotech dealmaking looks like in 2026
Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the surge in pharma M&A in 2025, ACA subsidies expiring, and more.
Novo Nordisk's Wegovy Pill Shakes Up Rivalry With Eli Lilly, Puts Health Care ETFs In Focus
The approval of Novo Nordisk's (NYSE: NVO)oral Wegovy is bringing new interest to health care and pharmaceutical ETFs that provide access to the growing GLP-1 market without requiring investors to cho...
This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter
CNBC's “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S. biotech analyst at Goldman Sachs Research.
3 Potential Mid-Cap Biotech Buyout Targets In 2026
The biotech sector began December with notable weakness, as both IBB and XBI ETFs declined over two percent during trading on Monday. The sector has bounced back since. However, small biotech stocks ...
iShares Biotechnology ETF: The M&A Wave Behind The Suddenly Booming Biotech Sector
The biotech sector, represented by the iShares Biotechnology ETF, has experienced a notable rally in recent months. The key driver of the 40% over the past six months has been a notable uptick in M&A ...
If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk the uptick in biotech and pharma M&A, what it is signaling, and how to play it.
'Fast Money' traders talk how to play biopharma space
The 'Fast Money' traders talk how to play biopharma space.
Biotech is back and a constructive place to put money to work, says Piper Sandler's Craig Johnson
Craig Johnson, Piper Sandler chief market technician, joins 'The Exchange' to discuss the market technicals, if its a real market rotation and much more.
Investing In Health Stocks - How Policy Clarity Is Opening Doors
The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discoun...
Trade Tracker: Jason Snipe buys the IBB
Jason Snipe, Founder and CIO of Odyssey Capital Advisors joins CNBC's “Halftime Report” to detail his latest purchase of the IBB.
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
‘Fast Money' traders talk opportunities in health care stocks
The Fast Money traders discuss why health care stocks look attractive on valuations, how underweight positioning could drive sustainability, why recent White House policy moves may be a “gift” to phar...
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz
Biotech is back – and it's playing for keeps. President Donald Trump's second-term policies have unleashed a staggering ~$350 billion surge in U.S.-based pharmaceutical and biotech investments, from d...
Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz
Jared Holz, Mizuho healthcare strategist, joins 'Power Lunch' to discuss the change in sentiment in the healthcare sector, the differences in the biotech ETFs and much more.
BBH Vs. IBB: How To Prepare For The Next Biotech Growth Cycle With BBH
Biotech is entering a new growth cycle driven by AI and CRISPR innovation, but current ETF valuations are high and volatility is elevated. BBH offers a concentrated portfolio of leading innovators wit...
Trump's deadline looms for Big Pharma companies facing new tariffs
'The Big Money Show' panel discusses President Donald Trump's pharmaceutical tariff strategy.
Heard on the Street: Why pharma stocks have outperformed the broader market since Trump threatened the industry with a 200% tariff
A generous grace period would give drugmakers time to sidestep most of the pain of looming duties.
Trump threatens 50% tariffs on copper, 200% on pharmaceuticals
However, the President did not disclose when the tariffs would take effect.
Biotech Looks Ready To Run, But ETFs, Which One? IBB Vs. XBI
IBB and XBI are similar in many ways, but their relative past performance does not tell the story. IBB is more concentrated, and that is ultimately why I prefer it to XBI. Both ETFs target a similar o...